Drugs News and Research

RSS

Research roundup: Evidence-based medicine consumer/expert divide; Pay for performance limitations; Improving community health centers

Health Affairs: Evidence That Consumers Are Skeptical About Evidence-Based Health Care - This survey of more than 1,500 patients with employer-based insurance found "there is a fundamental disconnect between the central tenets of evidence-based health care and the knowledge, values, and beliefs held by many consumers."

5 Jun 2010

Fox Chase Cancer Center announces first-in-human bi-specific HER2/HER3 pathway targeting antibody

Patients with HER2-positive cancers can have dramatic responses to HER2-targeted drugs but eventually develop resistance to the agents. With that problem in mind, Fox Chase Cancer Center researchers are testing a novel type of antibody called MM-111 in patients with HER2-positive disease who have progressed on standard therapy.

5 Jun 2010

Unsatisfactory interactions with physicians affect sickle cell disease patients' trust in medical profession

Faculty at the Johns Hopkins Berman Institute of Bioethics have published a study that shows, among adults with sickle cell disease, that unsatisfactory interactions with health-care providers in the past affect their trust in the medical profession more broadly.

5 Jun 2010

BMJ report questions WHO advisors' ties to pharmaceutical industry

"Key scientists behind World Health Organization advice on stockpiling of pandemic flu drugs had financial ties with companies which stood to profit," according to a joint investigation by BMJ in collaboration with the Bureau of Investigative Journalism, BBC News reports (6/4).

5 Jun 2010

John Theurer Cancer Center to showcase treatment advancements for cancer at ASCO 2010

The John Theurer Cancer Center at Hackensack University Medical Center announced today important research findings that will be presented at the American Society of Clinical Oncology annual meeting taking place June 4 - 8, 2010 in Chicago. Research highlights include a comparison of first-line treatments for an aggressive form of lymphoma, the efficacy and safety of a new genetically engineered cancer therapy, and the value of a commonly used tool for staging lymphoma.

5 Jun 2010

RTU announces phase 2 clinical trial results of UF-021 in patients with retinitis pigmentosa

Sucampo Pharmaceuticals, Inc. today confirmed that its partner, R-Tech Ueno, Ltd. reported the results of its recently completed phase 2 clinical trial of UF-021 in retinitis pigmentosa patients. The results showed improvement in visual function dose-dependently in both visual field test and subjective findings.

5 Jun 2010

Obama sets town hall meeting with seniors to tout Medicare rebate checks

President Barack Obama has scheduled a televised town hall meeting Tuesday in Wheaton, Md., "to trumpet one of the most popular provisions of his landmark health care bill: a $250 rebate to help Medicare beneficiaries pay for prescription drugs. ... An estimated 80,000 checks are scheduled to be sent in June, with others to follow on a rolling basis, to Medicare beneficiaries who enter the so-called 'doughnut hole' - a gap in prescription drug coverage that requires them to pay out of pocket" (Stolberg, 6/3).

5 Jun 2010

AHF applauds Gilead for offering pricing, access concessions to AIDS Drug Assistance Programs

AIDS Healthcare Foundation (AHF) lauded Gilead Sciences, maker of several key AIDS drugs, for its announcement earlier today that it will offer significant pricing and access concessions for the nation's beleaguered AIDS Drug Assistance Programs (ADAPs), the federally funded, state run programs that supply lifesaving AIDS drugs to low-income Americans in need.

5 Jun 2010

Boston hospitals increasingly scrutinized for costs while Buffalo hospitals will receive more Medicare funding

Officials in Gov. Deval Patrick's administration, "seeking to pressure hospitals as well as insurers to rein in costs, say they will more closely scrutinize plans for new medical buildings and technologies to determine how they might affect the cost of health care in Massachusetts.

5 Jun 2010

Ascalon International signs license agreement with CerRx

Ascalon International Inc., a newly established oncology drug developer, today announced an agreement for an exclusive option to license CerRx Inc's intravenous fenretinide product.

4 Jun 2010

Researchers induce memory of safety in brain of rats

Researchers have found a way to pharmacologically induce a memory of safety in the brain of rats, mimicking the effect of training. The finding suggests possibilities for new treatments for individuals suffering from anxiety disorders.

4 Jun 2010

ASCO 2010 marks first anniversary of "Cancer Patient Statement of Principles"

The International Myeloma Foundation (IMF), the oldest and largest foundation dedicated to improving the life and care of myeloma patients, notes the 2010 Annual Meeting of the American Society for Clinical Oncology (ASCO) marks the first anniversary of the "Cancer Patient Statement of Principles."

4 Jun 2010

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.

4 Jun 2010

Strategy for harnessing physics for health

Following a workshop hosted by the CERN European particle physics laboratory in February, doctors and physicists today published a strategy for harnessing physics for health. Techniques developed for physics research have a long history of application in medicine. Today's news recognises that synergy, and sets out a programme of strengthened collaboration.

4 Jun 2010

Caltech biologists pinpoint molecular changes that help allow global spread of resistance to Tamiflu

Biologists at the California Institute of Technology have pinpointed molecular changes that helped allow the global spread of resistance to the antiviral medication Tamiflu (oseltamivir) among strains of the seasonal H1N1 flu virus.

4 Jun 2010

Functional profiling using EVA/PCD for prescribing treatment regimens for Stage IV NSCLC improve survival

A team of investigators at Rational Therapeutics, Inc. and the Malcolm Todd Cancer Institute (Long Beach, Calif.) has reported that functional profiling using ex-vivo analysis of programmed cell death (EVA/PCD) can be used to prescribe treatment regimens that double the response rate and survival in patients with Stage IV non-small cell lung cancer (NSCLC). The findings of their phase II clinical trial will be presented on Sunday, June 6th at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

4 Jun 2010

Study: Rash adolescent behaviors tied to biological motivations

There are biological motivations behind the stereotypically poor decisions and risky behavior associated with adolescence, new research from a University of Texas at Austin psychologist reveals.

4 Jun 2010

Physicians and researchers to present 16 abstracts on cancer research at ASCO 2010

The John Theurer Cancer Center at Hackensack University Medical Center announced today that its physicians and researchers will present 16 abstracts on treatment and diagnostic progress in many different areas of oncology during the Annual Meeting of American Society of Clinical Oncology in Chicago, IL from June 4-8.

4 Jun 2010

Multiple sclerosis risk sharing scheme: A costly failure

The multiple sclerosis risk sharing scheme is "a costly failure" and should not be continued, according to researchers on bmj.com today. They argue that the biggest losers are the other NHS patients who would otherwise have benefited from the money spent on the scheme, estimated to be around -50m per year since it was set up in 2002.

4 Jun 2010

Ongoing clinical development program for NX-1207 for treatment of BPH highlighted

Nymox Pharmaceutical Corporation is pleased to report on the presentation of new positive data at a high-level symposium and panel discussion held at the Annual Meeting of the American Urological Association in San Francisco. The symposium was held between 6:00 and 7:00 pm EDT on Tuesday. The well-attended symposium highlighted the ongoing clinical development program for NX-1207 for the treatment of benign prostatic hyperplasia and featured expert panel discussions on the new therapy.

4 Jun 2010

Drugs News and Research

Research roundup: Evidence-based medicine consumer/expert divide; Pay for performance limitations; Improving community health centers

Fox Chase Cancer Center announces first-in-human bi-specific HER2/HER3 pathway targeting antibody

Unsatisfactory interactions with physicians affect sickle cell disease patients' trust in medical profession

BMJ report questions WHO advisors' ties to pharmaceutical industry

John Theurer Cancer Center to showcase treatment advancements for cancer at ASCO 2010

RTU announces phase 2 clinical trial results of UF-021 in patients with retinitis pigmentosa

Obama sets town hall meeting with seniors to tout Medicare rebate checks

AHF applauds Gilead for offering pricing, access concessions to AIDS Drug Assistance Programs

Boston hospitals increasingly scrutinized for costs while Buffalo hospitals will receive more Medicare funding

Ascalon International signs license agreement with CerRx

Researchers induce memory of safety in brain of rats

ASCO 2010 marks first anniversary of "Cancer Patient Statement of Principles"

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Strategy for harnessing physics for health

Caltech biologists pinpoint molecular changes that help allow global spread of resistance to Tamiflu

Functional profiling using EVA/PCD for prescribing treatment regimens for Stage IV NSCLC improve survival

Study: Rash adolescent behaviors tied to biological motivations

Physicians and researchers to present 16 abstracts on cancer research at ASCO 2010

Multiple sclerosis risk sharing scheme: A costly failure

Ongoing clinical development program for NX-1207 for treatment of BPH highlighted

Drug Discovery - Second Edition eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News